CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Like
Comment
Favorite

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

GlobeNewswire10-29

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2479068564?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc","is_english":true,"pubTime":"2024-10-29 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479068564","market":"us","top_or_hot":-1,"title":"CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference","media":"GlobeNewswire","content":"<div>\n<p>Topline data from the RewinD-LB Phase 2b study on track for December 2024\nDetailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference...</p>\n\n<a href=\"https://finance.yahoo.com/news/cervomed-deliver-oral-presentation-8th-120000353.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cervomed-deliver-oral-presentation-8th-120000353.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Topline data from the RewinD-LB Phase 2b study on track for December 2024\nDetailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference...</p>\n\n<a href=\"https://finance.yahoo.com/news/cervomed-deliver-oral-presentation-8th-120000353.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/cervomed-deliver-oral-presentation-8th-120000353.html","article_id":"2479068564","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xD1TTTZoqyWtGhy773ezlw--~B/aD0xMjc7dz00MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/385dc1ddc05fe2c5223b5b9ca399d0fc"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479068564","pubTimestamp":1730203200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Topline data from the RewinD-LB Phase 2b study on track forDecember 2024. Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025. BOSTON, Oct. 29, 2024  -- CervoMed Inc. , a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies  at the eighth International Lewy Body Dementia Conference  taking place on January 29-31, 2025 in Amsterdam, the Netherlands.This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the therapeutic potent","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DLB":"杜比","CRVO":"CervoMed","BK4097":"系统软件","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC"},"translate_title":"CervoMed将在第八届国际路易体痴呆会议上发表口头报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":1,"DLB":1},"content_text":"Topline data from the RewinD-LB Phase 2b study on track for December 2024\nDetailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025\nBOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the eighth International Lewy Body Dementia Conference (ILBDC) taking place on January 29-31, 2025 in Amsterdam, the Netherlands.\n“As we await topline results from the RewinD-LB Phase 2b trial in DLB, we are extremely encouraged by the scientific community’s interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to Lewy Body Dementia,” said John Alam, MD, Chief Executive Officer of CervoMed. “There are currently no approved therapies for DLB, and the dementia clinical research community has a strong interest in the ongoing RewinD-LB Phase 2b study and its potential beneficial impact to patients and families. Topline results for RewinD-LB are expected to be disclosed in December 2024 and we are also presenting data on RewinD-LB baseline patient characteristics at the upcoming Clinical Trials on Alzheimer's Disease Conference (CTAD). Based on our preliminary analyses, we are confident that we have optimized RewinD-LB trial design to detect a statistically significant and clinically meaningful difference between neflamapimod and placebo.”\nDetails of the ILBDC presentation are as follow:Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationSession Name: Therapeutics in DLBSession Date and Time: Friday, January 31, 2025, 14.00-15.30 pm Local Time\nAbout CervoMed\nCervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.\nForward-Looking Statements\nThis press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the therapeutic potential of neflamapimod and the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company’s announcement of topline and other data therefrom. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “might,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources and the availability of additional funds on acceptable terms; the results of the Company’s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.\nInvestor Contact:\nPJ KelleherLifeSci AdvisorsInvestors@cervomed.com617-430-7579","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Important Conferences","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}